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Abstract 
Background: HIV‑1 Vif interacts with the cellular core‑binding factor β (CBFβ) and counteracts the protective roles 
of certain human APOBEC3 (A3) proteins by targeting them for proteasomal degradation. Previous studies have 
identified some amino acids important for Vif–CBFβ interactions, and recently a co‑crystal structure of a pentameric 
complex of HIV‑1 Vif, CBFβ, Cul5, EloB, and EloC was resolved. However, a comprehensive analysis of Vif–CBFβ interac‑
tions that are important for Vif function has not been performed.
Results: Here, we carried out double‑alanine scanning mutagenesis of the first 60 amino acids of Vif and determined 
their effects on interaction with CBFβ and their ability to induce A3G degradation as well as rescue HIV‑1 replication 
in the presence of A3G. We found that multiple Vif residues are involved in the extensive N‑terminal Vif–CBFβ interac‑
tion and that the 5WQVMIVW11 region of Vif is the major determinant. A minimum of three alanine substitutions are 
required to completely abrogate the Vif–CBFβ interaction and Vif’s ability to rescue HIV‑1 infectivity in the presence of 
A3G. Mutational analysis of CBFβ revealed that F68 and I55 residues are important and participate in a tripartite hydro‑
phobic interaction with W5 of Vif to maintain a stable and functional Vif–CBFβ complex. We also determined that 
CBFβ amino acids 73WQGEQR78, which are not resolved in the structure of the pentameric complex, are not involved 
in interaction with HIV‑1 Vif.
Conclusions: Our results provide detailed insight into the Vif–CBFβ interactions that are critical for Vif function and 
may contribute to the rational design of HIV‑1 inhibitors that block Vif‑mediated degradation of A3 proteins.
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Background
HIV-1 and other lentiviruses encode the accessory 
protein Vif that counteracts the antiviral activities of 
APOBEC3 (A3) proteins and is required for infection and 
propagation in primary CD4+ T cells and in non-permis-
sive T cell lines (for recent reviews see Refs. [1, 2]). Vif 
neutralizes the inhibitory activities of A3 proteins by tar-
geting them for polyubiquitination and proteasomal deg-
radation by hijacking an E3 ubiquitin ligase complex [3].
Jager et  al. [4] and Zhang et  al. [5] recently reported 
that in addition to binding to cullin 5 (Cul5) and elongin 
B/C (EloB/C), Vif binds to the cellular core-binding fac-
tor β (CBFβ), and the Vif–CBFβ interaction is essential 
for inducing efficient degradation of A3 proteins, which 
inhibit HIV-1 replication in non-permissive cell types. 
CBFβ is an evolutionarily conserved non-DNA binding 
component of the mammalian runt-related transcription 
factors (RUNX 1-3), which are critical in hematopoiesis, T 
cell differentiation, and skeletal development [6, 7]. CBFβ 
is an allosteric regulator of RUNX proteins and has previ-
ously been reported to stabilize RUNX1 by preventing its 
ubiquitin-mediated degradation [8]. Recently, CBFβ was 
proposed to play a critical role in stabilizing the intrinsi-
cally unstructured HIV-1 Vif and promoting formation of 
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a well-ordered substrate receptor by facilitating local fold-
ing of the N-terminal Vif region [4, 5, 9–11].
Several reports have established that HIV-1 Vif inter-
acts with CBFβ and have shown that CBFβ depletion 
hampers virus replication in cells expressing A3 proteins 
primarily by interfering with Vif ’s ability to induce deg-
radation of the A3 proteins [4, 5, 9]. HIV-1 Vif associ-
ates with CBFβ in human cells and recombinant CBFβ 
enhances Vif ’s solubility, stability, and association with an 
E3 ubiquitin ligase complex [9, 10, 12–14]. Initially, the 
interaction interface was mapped to residues 15–126 of 
CBFβ [9, 15]; CBFβ amino acid F68 was then reported 
to be critical for stable HIV-1 Vif–CBFβ interaction [14]. 
Subsequently, an X-ray crystal structure of five penta-
meric complexes, each containing CBFβ–Vif–EloB/C-
Cul5, was determined [10]. In the pentameric complex, 
HIV-1 Vif is tightly associated with CBFβ and interacts 
with both EloC and Cul5.
Determining the biological relevance of the critical 
residues of Vif that govern the specificity of the Vif–
CBFβ interaction can facilitate our understanding of this 
important host–virus interaction. Additionally, elucidat-
ing this interaction at the molecular level can potentially 
assist in the design of inhibitors that block Vif–CBFβ 
binding and thereby interfere with Vif function. Previous 
mutational analyses identified several residues of Vif that 
were important for its interaction with CBFβ [10, 16–18]. 
Of particular relevance to this work, Fribourgh et al. [16] 
reported that deletion of the first 13 amino acids of Vif 
abolished the interaction of recombinant Vif with CBFβ, 
consistent with the crystal structure data, which showed 
that there are extensive interactions between the N-ter-
minal hydrophobic anti-parallel β-strands of HIV-1 Vif 
and CBFβ [10].
To determine the functional importance of these exten-
sive N-terminal HIV-1 Vif–CBFβ interactions, we ana-
lyzed double-alanine mutants of the first 60 amino acids 
of HIV-1 Vif and determined the effects of the muta-
tions on CBFβ binding by co-immunoprecipitation. We 
found that 5WQVMIVW11 region of Vif is important 
for the Vif–CBFβ interaction, of which W5 is the most 
critical determinant. We also found that H27–H28 and 
D37–W38 influence CBFβ binding eventhough they are 
not at the CBFβ–Vif interface in the pentameric com-
plex, suggesting that they indirectly affect the interac-
tion with CBFβ. We also observed that CBFβ amino acids 
73WQGEQR78, which are in close proximity to residues 
E45–S52 of Vif and are not resolved in the pentameric 
complex crystal structure, do not contribute to the Vif–
CBFβ interaction. Finally, consistent with the crystal 
structure, our mutational analysis indicated that CBFβ 
amino acids I55 and F68 form a tripartite interaction 
with W5 of Vif that is critical for Vif function.
Results
Identification of HIV‑1 Vif determinants that are important 
for interaction with CBFβ
To identify HIV-1 Vif determinants that are essential for 
interaction with CBFβ, we used a previously described 
panel of single or double-alanine substitution mutants 
of the first 60 amino acids of Vif [19]. Our alanine-scan-
ning mutagenesis screen focused primarily on identify-
ing residues that abrogated the interaction between Vif 
and CBFβ as determined by co-immunoprecipitation 
(co-IP) assays (Fig.  1). We co-transfected 293T cells 
with plasmids encoding Flag-CBFβ and untagged Vif 
mutants, performed co-IP assays using anti-Flag anti-
body and lysates of the co-transfected cells and estimated 
the amounts of Vif proteins that co-immunoprecipitated 
with Flag-CBFβ using quantitative western blotting 
analysis (Fig.  1). The levels of the different Vif mutant 
proteins were comparable when they were expressed in 
the presence of Flag-CBFβ (Fig. 1a, b). The efficiency of 
CBFβ binding to wild-type (WT) Vif was set to 100%, 
and used to compare the binding efficiencies of the Vif 
mutants (Fig. 1b, c). The average binding efficiencies from 
five independent experiments are shown below for each 
mutant. Notably, of the mutants examined, W5A–Q6A, 
I9A–V10A, H27A–H28A, and D37A–W38A significantly 
reduced Vif ’s ability to bind to CBFβ compared to WT 
Vif (Fig. 1b; values indicated in green). The H27A–H28A 
and D37A–W38A amino acids are not at the Vif–CBFβ 
interface. The solvent accessible surface area (SASA; 
determined by using getarea program available at http://
curie.utmb.edu/getarea.html) for H28 is only 4.86  Å2, 
and W38 is not surface exposed (SASA is 0.0  Å2), sug-
gesting that these amino acids are buried in the Vif pro-
tein, and substitution of these amino acids with alanines 
may have disrupted the overall structure of the α-domain 
of Vif. The locations of these amino acids are shown in 
Fig.  1d. In addition, mutations in the E45–P58 strand–
helix–loop structure of Vif also exhibited partial defects 
in binding to CBFβ; mutant E45A–S46A, T47–N48A, 
S53A–E54A, V55A–H56A, and I57A–P58A showed sig-
nificantly lower binding than WT Vif (Fig.  1c, d; values 
indicated in green). These results led to the identification 
of several amino acids in the N-terminal Vif region that 
are critically important for binding to CBFβ.
The pentameric structure [10] indicated that the Vif 
amino acids from W5–W11 are in close proximity to 
CBFβ amino acids N63–F68 and I55; each of the Vif 
amino acids is within 3.46–5.99 angstroms (Å) of the 
CBFβ amino acids, suggesting that any or all of these Vif–
CBFβ interactions could be critical for Vif function. The 
importance of the W5–W11 amino acids of Vif is sup-
ported by a previous study [16] indicating that deleting 
the first 13 amino acids of Vif abolishes the interaction 
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Fig. 1 Identification of Vif determinants that are critical for binding to CBFβ. a A schematic of Vif structure and its interaction domains with cellular 
proteins APOBEC3F (A3F), APOBEC3G (A3G), cullin 5 (Cul5) and elongin C (EloC). Double alanine mutants of the first 60 amino acids of Vif were 
analyzed. b Immunoblots of cell lysates to detect Flag‑CBFβ, Vif, and tubulin (used as loading control). c Immunoblots of WT and mutant Vifs that 
co‑immunoprecipitated with Flag‑CBFβ. The average binding efficiency of Vif mutants to CBFβ from five independent transfection experiments is 
shown below each lane relative to WT Vif (set to 100%). Statistical significance was determined using t test; *P < 0.05. The mutants with significantly 
reduced Vif–CBFβ binding are shown in green; mutants with increased Vif–CBFβ binding are shown in red. The upper bands of the Vif IP blots of 
Q12A‑V13A and WT (the last panel) are most likely the light chains of the anti‑Flag antibody used for immunoprecipitation. d A ribbon diagram of 
HIV‑1 Vif; the highlighted residues 5WQVMIVW11, H27–H28, D37–W38, 45ESTN48, and 53SEVHIP58 decrease CBFβ binding efficiency as shown in (c). Vif 
45ESTNPKIS52 residues are in a loop and beginning of a β‑strand; these Vif amino acids are near a loop of CBFβ that was not resolved in the structure 
(75GEQRQPT81, purple dashed line). Vif is shown in red and CBFβ is shown in cyan (PDB:4N9F)
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between Vif and CBFβ. Our results indicating that the 
double mutants W5A–Q6A and I9A–V10A disrupt the 
interaction with CBFβ, but the V7A–M8A and W11A 
mutants did not, indicated that some of these amino 
acids are critical for the interaction while others are 
less important. Surprisingly, our results showed that the 
H27A–H28A and D37A–W38A mutants severely ham-
pered the interaction between Vif and CBFβ in our bind-
ing assay; these amino acids are 11–15 Å away from the 
nearest CBFβ amino acid (R151) in the pentameric struc-
ture and are not at the interaction interface (PDB:4N9F) 
[10]. Analysis of the structure of Vif [10] suggested 
that W38, I57, I107, Y111, and F112 are involved in an 
extensive hydrophobic interaction that maintains the 
structural organization of the α-domain of HIV-1 Vif 
(Additional file 1: Supplementary Fig. S1), implying that 
they indirectly affect the interaction with CBFβ.
Our observations that the double mutants W5A–Q6A 
and I9A–V10A disrupt the interaction with CBFβ in cells 
provide functional insights into the recently reported 
structural information of the pentameric complex [10], 
which showed that amino acids 5WQVMIVW11 interact 
with CBFβ. We also found that amino acids E45–P58 of 
Vif, which forms a flexible loop [10], influenced the Vif–
CBFβ interaction. Amino acids E45–S52 are in a posi-
tion to potentially form direct interactions with amino 
acids W73–R78 of CBFβ. However, this region of CBFβ 
was not resolved in the pentameric complex [10]; thus, a 
potential direct interaction between these amino acids of 
Vif and CBFβ could not be verified or excluded based on 
the crystal structure. Finally, we also observed that N3A–
R4A, Q12A–V13A, M16A–R17A, N19A–T20A, and 
R23A–L24A mutants exhibited a significantly higher effi-
ciency of binding to CBFβ compared to WT Vif (Fig. 1b; 
values indicated in red); the potential biological signifi-
cance of increased binding to CBFβ by these mutants was 
not further examined in these studies.
Effects of CBFβ‑binding mutations on Vif’s ability to induce 
A3G degradation and rescue HIV‑1 infectivity
Next, we examined whether the Vif mutants that exhib-
ited reduced binding to CBFβ showed a defect in their 
ability to induce A3G degradation and inhibit HIV-1 rep-
lication. We co-transfected 293T cells with HDV-GFP, 
VSV-G, and WT Vif (or Vif mutants) in combination 
with different amounts of A3G expression plasmids and 
examined the ability of the Vif mutants to mediate A3G 
degradation and rescue infectivity of HIV-1 (Fig.  2). In 
addition to the Vif mutants that were defective in CBFβ 
binding, we included V7A–M8A and W11A because they 
can potentially contribute to the extensive hydrophobic 
interaction between Vif and CBFβ anti-parallel β-strands. 














































































































































































































































Fig. 2 Effect of selected double‑alanine mutations in Vif on A3G 
degradation and HIV‑1 infectivity. a Stick diagram of amino acids at 
the Vif–CBFβ interface. 5WQVMVIW11 amino acids of Vif and amino 
acids 55–68 of CBFβ, and the interaction between W5 of Vif with I55 
and F68 of CBFβ are shown. b Representative immunoblots of Flag‑
A3G, Vif, and tubulin (loading control). Degradation of Flag‑A3G was 
determined by co‑transfection of either 0.34 or 0.67 μg of Flag‑A3G 
expression plasmid. c Quantitation of Vif‑induced A3G degradation 
relative to the no Vif control (which was set to 100%) is shown. Bar 
graphs represent mean and standard deviations of two or more 
independent transfection experiments and statistical significance was 
determined using t test; *P < 0.05. d Infectivity of viruses in the pres‑
ence of different Vif mutants. Data (mean ± SDs from two or more 
independent experiments done in triplicates) are plotted relative to 
viruses produced in the presence of WT Vif (set to 100%). Statistical 
significance was determined using t test; *P < 0.05
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and I51–S52A, because of their proximity to other double 
mutants that showed significant defects in CBFβ binding. 
Vif mutants W5A–Q6A, H27A–H28A, D37A–W38A, 
T47A–N48A, P49A–K50A, and I51A–S52A exhibited 
significant defects in their ability to mediate A3G degra-
dation compared to WT Vif (Fig. 2b, c). Mutants V7A–
M8A, I9A–V10A, W11A, and E45A–S46A induced A3G 
degradation as well as WT Vif. We next compared the 
infectivity of viruses produced in the presence of these 
Vif mutants to WT Vif (set to 100%); infectivity was sig-
nificantly reduced for all of the mutants except V7A–
M8A (Fig. 2d). Although the steady-state levels of A3G in 
the presence of W11A and E45A–S46A Vif mutants were 
similar to the level of A3G in the presence of WT Vif 
(Fig. 2b, c), there was a two-fold reduction in the infec-
tivity of viruses produced in the presence of these Vif 
mutants (Fig. 2d). These results indicate that when A3G 
levels are low and barely detectable on western blots, 
virus infectivity is a more sensitive measure of the levels 
of A3G remaining than western blotting. Taken together, 
these results strongly indicate that Vif residues W5–Q6, 
I9–V10, H27–H28, D37–W38, and the loop region E45–
S52 are critical for Vif ’s ability to bind to CBFβ, induce 
A3G degradation, and rescue infectivity.
Effect of reducing the level of CBFβ on the ability of Vif 
mutants to degrade A3G and rescue HIV‑1 infectivity
Vif amino acids 5WQVMIVW11 form a β-strand that is 
at the CBFβ interface [10]; however, our alanine-scan-
ning mutagenesis suggested that only W5A–Q6A and 
I9A–V10A mutants significantly reduced the interaction 
with CBFβ. We hypothesized that the other amino acids 
in the 5WQVMIVW11 motif contribute to CBFβ bind-
ing, but because there are high levels of CBFβ in 293T 
cells, modest reductions in CBFβ binding would not be 
observed in our co-IP assays. We therefore sought to 
assess whether reducing CBFβ levels in cells by siRNA 
knockdown would more readily reveal minor interac-
tions that contribute to Vif–CBFβ binding. We first 
determined the effect of CBFβ depletion on A3G deg-
radation by transfecting either a CBFβ-specific siRNA 
or a control siRNA (Fig. 3a, b). The results showed that 
the CBFβ-specific siRNA-mediated knockdown reduced 
CBFβ protein to 4.9–9.0% of the levels in the presence of 
control siRNA. We also determined the combined effect 
of CBFβ knockdown and Vif mutants on infectivity of 
viruses produced in the presence of 0.34 μg or 0.67 μg of 
A3G plasmid (Fig. 3c). The results showed that virus pro-
duced in cells with reduced levels of CBFβ and WT Vif 
resulted in further reduced infectivity compared to the 
infectivity in the presence of control siRNA (18 and 6% 
in the presence of 0.34 and 0.67 μg of A3G, respectively). 
When CBFβ was depleted and the V7A–M8A and W11A 
mutants were expressed, we observed a more significant 
defect in restoring virus infectivity (8 and 4% of the WT 
Vif in the presence of control siRNA, respectively). Thus, 
in the presence of normal levels of CBFβ, the V7A–M8A 
and W11A mutants either showed no defect or a mod-
est twofold defect in rescuing virus infectivity compared 
to WT Vif (Fig. 3c), but in CBFβ-depleted cells, the same 
mutants showed significant defects in rescuing virus 
infectivity (approximately threefold and 4.5-fold, respec-
tively). Taken together, these data indicate that the V7A–
M8A and W11 residues do make a minor contribution to 
CBFβ binding, but their contribution to CBFβ binding is 
dependent on the CBFβ protein expression level.
Effect of Vif quadruple– and triple–alanine substitution 
mutations 5WQVM8 > 4A and 9IVW11 > 3A on interaction 
with CBFβ and A3G degradation
The double-alanine substitution mutations in 
5WQVMIVW11 binding motif of HIV-1 Vif did not 
completely abolish CBFβ binding, suggesting that mul-
tiple residues are involved in the interaction between 
Vif and CBFβ [10]. Moreover, single-alanine substitu-
tion mutagenesis in the 5WQVMIVW11 motif of Vif 
revealed that only the W5A mutant significantly affected 
Vif ’s activity against A3G and failed to rescue infectivity 
(Additional file  2: Supplementary Fig. S2). Because sin-
gle amino acid substitutions 6QVMIVW11 did not have 
a significant effect on Vif–CBFβ binding, we sought to 
determine whether combining multiple substitutions in 
this region would influence Vif interaction with CBFβ. 
We constructed two additional mutants in which four or 
three Vif amino acids were substituted with alanines to 
generate 5WQVM8 > A4 and 9IVW11 > A3 Vif mutants. 
Consistent with our hypothesis, both 5WQVM8 > A4 and 
9IVW11  >  A3 mutants almost completely eliminated Vif 
binding to CBFβ with binding efficiencies of 2 and 0.3%, 
respectively (Fig. 4a, b).
Next, we determined the effects of the quadruple– and 
triple–alanine substitution mutations in Vif on A3G deg-
radation and infectivity (Fig. 4c–e). We found that both 
5WQVM8 > A4 and 9IVW11 > A3 mutants failed to medi-
ate A3G degradation (Fig.  4c, d) and rescue infectivity 
when viruses were produced in cells that co-expressed 
A3G (Fig.  4e). These data suggest that the N-terminal 
interaction between HIV-1 Vif and CBFβ is stabilized by 
hydrophobic interactions and at least three alanine sub-
stitutions are required to abolish the interaction between 
the anti-parallel β-strands of Vif and CBFβ [10].
73WQGEQR78 residues of CBFβ are not important for stable 
Vif–CBFβ interaction
After identifying the Vif determinants that inter-
act with CBFβ, we sought to determine the role of 
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CBFβ determinants that are in close proximity to Vif 
in the co-crystal structure and may contribute to the 
Vif–CBFβ binding [10]. We first investigated whether 
73WQGEQRQTPS82 residues in a flexible strand-loop 
region of CBFβ are important for interaction with Vif 
residues E45–S52 (Fig. 5a). Unfortunately, the CBFβ resi-
dues 75GEQRQTP81 are not resolved in the pentameric 
crystal structure [10] (Fig. 5a; dashed line). After analy-
sis of the pentameric structure, we decided to investigate 
73WQGEQR78 residues, which are potentially in close 
proximity to the Vif residues E45–S52.
We generated CBFβ mutants W73A–Q74A, G75A–
E76A, and Q77A–R78A and determined their ability to 
interact with Vif (Fig.  5b, c). To examine the effects of 
these CBFβ double mutations on Vif binding, we first 
knocked down the endogenous CBFβ in 293T cells using 
an siRNA that binds to the 3′ untranslated region of the 
CBFβ mRNA; the efficiency of knockdown was >90% 
(Fig. 5b). We then expressed wild-type Flag-CBFβ or its 
mutants and determined the effects of the mutations on 
steady-state levels of Flag-A3G. We found that none of 
these CBFβ double mutants had a measurable effect on 
the interaction between CBFβ and Vif compared to wild-
type CBFβ (Fig. 5b, c), suggesting that the 73WQGEQR78 
residues are not required for the Vif–CBFβ interaction.
A tripartite interaction between I55 and F68 of CBFβ 
and W5 of Vif is critical for stable Vif–CBFβ binding
The major interaction between CBFβ and N-terminal Vif 
residues involves two anti-parallel β-strands. Based on 
the pentameric crystal structure, the distance between 






















































































































































































Fig. 3 Effect of combination of double‑alanine Vif mutants in CBFβ‑depleted cells on Vif activity. a Representative western blots showing levels of 
A3G, Vif, CBFβ, and tubulin in cells co‑transfected with Flag‑A3G, Vif variants, and CBFβ‑specific siRNA or control siRNA. Lysates of virus producer cells 
were collected 48 h post‑transfection and analyzed by western blotting. Tubulin was used as a loading control for quantitation A3G levels. Quantita‑
tion of CBFβ knockdown efficiency from two independent experiments is depicted below each lane. b Quantitation of Vif‑induced A3G degrada‑
tion relative to the no Vif control (control siRNA; set to 100%) from two independent experiments. c Infectivity of viruses produced in experiments 
shown in (a) is plotted relative to virus produced in the presence of WT Vif and control siRNA (set to 100%; not shown). Infectivity was determined 
by measuring luciferase activity in TZM‑bl cells. Statistical significance was determined using t test; *P < 0.05
























































































































































































































Fig. 4 Effect of quadruple– and triple–alanine substitution mutants 
of Vif on CBFβ interaction and A3G degradation. Comparison 
of selected double, quadruple– (5WQVM8 > 4A), and triple– 
(9IVW11 > 3A) alanine substitution mutants of Vif with respect to CBFβ 
binding, A3G degradation, and ability to rescue virus infectivity. a 
Representative immunoblots of cell lysates (upper three panels) and 
co‑IP (lower panel) probed for Flag‑CBFβ, Vif, and tubulin (loading 
control) are shown. b Average efficiency with which Vif mutants bind 
to CBFβ from two independent transfection experiments relative to 
WT Vif (set to 100%). Statistical significance was determined using 
t test; *P < 0.05. c A representative immunoblot showing the effect 
of Vif mutants on A3G degradation. d Quantitation of relative A3G 
levels compared to the no Vif control (set to 100%). Error bars indicate 
standard deviations from four independent experiments. Statistical 
significance was determined using t test; *P < 0.05. e Infectivity of 
viruses produced in 293T cells in the presence of Flag‑A3G and the 
indicated Vif mutants; mean ± SDs are for virus stocks obtained from 
two independent transfection experiments; virus infectivity of each 
virus stock was an average of three infections. All comparisons were 
based on viruses produced in the presence of WT Vif (set to 100%). 
Statistical significance was determined using t test; *P < 0.05
▸
F68 is 4.4  Å. We hypothesized that W5 of Vif and I55 
and F68 residues of CBFβ form a tripartite interaction 
that is critical for Vif–CBFβ binding. To confirm that this 
interaction is important in cells, we mutated the CBFβ 
residues I55 and F68 and measured the impact that these 
mutations had in co-IP assays in which the endogenous 
CBFβ was depleted by siRNA. Hultquist et al. previously 
showed that the F68D mutant of CBFβ differentially 
abrogated the interaction between CBFβ and Vif while 
preserving CBFβ’s ability to bind to its cellular interaction 
partner RUNX1 [14]. In addition to the F68D mutant, we 
generated CBFβ mutants I55A, I55D, F68A, I55A–F68D, 
and I55D–F68D and examined their ability to interact 
with Vif (Fig.  6). To examine the effects of the muta-
tions in CBFβ on Vif binding, we first knocked down 
the endogenous CBFβ in 293T cells using siRNAs that 
bind to the 3′ untranslated region of the CBFβ; the effi-
ciency of knockdown was >90%. We then expressed Flag-
tagged wild-type CBFβ or its mutants and determined 
the effect of the mutations on steady-state levels of Flag-
A3G (Fig.  6a, b). The results showed that, compared to 
CBFβ-WT, the I55A and I55D mutants were less efficient 
at restoring virus infectivity in the presence of 0.34 and 
0.67 μg of A3G. The F68A substitution did not influence 
Vif–CBFβ interaction in this assay and could restore virus 
infectivity to the same extent as CBFβ–WT. In agreement 
with previously reported results [14], the F68D mutant 
was unable to rescue virus infectivity, as were both the 
I55A–F68D and I55D–F68D double mutants (Fig. 6a, b). 
These results indicated that in addition to F68, I55 affects 
Vif–CBFβ interaction.
Finally, we examined the ability of the CBFβ mutants 
to bind to HIV-1 Vif (Fig.  7a, b). Both I55A–F68D and 
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I55D–F68D CBFβ double mutants almost completely 
failed to bind to Vif, reducing binding efficiency to ~8% of 
that observed for CBFβ-WT in the co-IP assay (Fig. 7b). 
Individually, the I55D and F68D mutants significantly 
reduced Vif binding to ~15 and ~28% compared to that 
of CBFβ-WT, respectively (Fig.  7b), suggesting that dis-
ruption of the tripartite interaction almost completely 
inhibits the Vif–CBFβ interaction. As expected, substi-
tuting I55 with the less bulky hydrophobic residue (A55) 
had only a modest effect on Vif binding (Fig. 7a, b). Taken 
together, these results show that the tripartite interaction 
between I55 and F68 of CBFβ and W5 of Vif is critical for 
Vif ’s ability to induce A3G degradation and restore virus 
infectivity (Fig. 7c).
Discussion
The list of host proteins in the Vif interactome is expand-
ing and among these are EloB/C, CUL5, and CBFβ, which 
are essential for counteracting the antiviral activities of 
A3 proteins by targeting them for proteasomal degrada-
tion [4, 5, 10, 20–22]. Thus, the Vif–CBFβ interaction is 
a potential target for development of antiviral agents that 
interfere with Vif ’s ability to induce degradation of A3 
proteins. The recently reported pentameric crystal struc-
ture of Vif–CBFβ–CUL5–EloB/C has provided valuable 
structural information about this interaction [10], and 
has indicated that the interface is stable primarily due 
to extensive hydrophobic interactions involving a large 
surface area (4797 Å2). Although the extensive nature of 
this protein–protein interaction suggests that small mol-
ecules are unlikely to disrupt the Vif–CBFβ interaction, 
it is possible that specific determinants of this interac-
tion are essential for Vif function, and such functionally 
relevant determinants could provide targets for anti-



























































































Ctrl  siRNACBFβ  siRNA
Fig. 5 Effect of mutations in the 73WQGEQR78 region of CBFβ on 
Vif–CBFβ interaction. a A ribbon diagram of HIV‑1 Vif and CBFβ; 
Vif residues 45ESTNPKIS52 are shown in orange and CBFβ residues 
73WQGEQR78 are shown in purple. The dashed line indicates loop 
region of CBFβ that was not resolved in the structure. Vif is shown 
in red and CBFβ is shown in cyan (PDB: 4N9F). b After transfection 
of 293T cells with CBFβ‑specific or control siRNA, the cells were co‑
transfected with WT CBFβ or double‑alanine substitution mutants of 
CBFβ and WT Vif. Immunoblots of cell lysates (upper panel) and co‑IP 
samples (lower panel) probed for Flag‑CBFβ, endogenous CBFβ, Vif, 
and tubulin (loading control) are shown. c The bar graphs represent 
the average immunoprecipitation efficiency of the different CBFβ 
mutants to WT Vif relative to WT CBFβ (set to 100%). None of the 
mutations had a measurable effect on CBFβ levels or on Vif–CBFβ 
binding
▸
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determine which Vif–CBFβ interactions are essential for 
Vif function by performing alanine scanning mutagenesis 
of the first 60 amino acids of Vif. Our results show that 
Vif residues 5WQVMIVW11 play a critical role in bind-
ing to CBFβ; specifically, our results indicate that W5 
of Vif forms a critical tripartite interaction with I55 and 
F68 of CBFβ. Substitution of any one of these three resi-
dues almost completely abolished the binding of Vif to 
CBFβ, as determined in Co-IP assays. Mutation of W5 of 
Vif abolished Vif ’s ability to induce degradation of A3G, 
and mutants of CBFβ with substitutions at the I55 and 
F68 positions failed to rescue Vif ’s function when the 
endogenous CBFβ was depleted by siRNA knockdown. 
Our results confirm a previous study indicating that 
F68D mutation of CBFβ abrogated Vif–CBFβ interac-
tion without affecting the formation of the CBFβ-RUNX1 
heterodimer [14], and other studies [16, 18] which indi-
cated that Vif amino acids 5WQVMIVW11 are important 
for CBFβ binding. Unlike the previous studies, which 
performed deletion and substitution mutation analysis 
in the absence of a structure, we performed a rational, 
structure-based systematic analysis to map the amino 
acid determinants that are functionally critical for Vif–
CBFβ interaction. Importantly, our results indicate that 
the W5 of the 5WQVMIVW11 is critical for CBFβ bind-
ing and participates in a tripartite interaction with CBFβ 
residues I55 and F68, while other amino acids make 
minor contributions to CBFβ binding. We also showed 
that residues of a disordered loop of CBFβ (amino acids 
73–78 of loop 3), which are not modeled in the crystal 
structure due to poorly defined electron density, are dis-
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Fig. 6 Identification of CBFβ mutants that are defective in Vif binding and restoring infectivity in the presence of A3G. a Representative western 
blots of 293T cells co‑transfected with CBFβ siRNA or control siRNA, along with Flag‑CBFβ, WT Vif, and 0.34 or 0.67 μg of Flag‑A3G. The blots show 
Flag‑A3G, Flag‑CBFβ, endogenous CBFβ, WT Vif, and tubulin (loading control). b Infectivity of viruses produced in experiments shown in (a) as deter‑
mined by measuring luciferase activity in TZM‑bl cells. The bar graphs represent relative infectivity compared to no A3G samples (set to 100%). All 
data represent mean ± SDs from two independent transfection experiments; virus infectivity for each virus stock was an average of three infections. 
Statistical significance was determined using t test; *P < 0.05
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We found that the other amino acids in the 
5WQVMIVW11 motif did contribute to the interaction 
with CBFβ, but 3 or 4 alanine substitution mutations 
were required to completely abolish CBFβ binding. The 
5WQVMIVW11 forms a β strand that makes β barrel-like 
interactions with the β2 and β3 strands of CBFβ. Since 
backbone hydrogen bonds, and not side-chain bonds, are 
critical for formation of β barrels, it is possible that multi-
ple alanine substitutions are required to alter the second-
ary structure of this motif, resulting in loss of interaction 
with CBFβ.
Our results indicated that Vif amino acids E45–S52 
played a role in Vif–CBFβ binding. The exact mechanism 
by which these Vif residues contribute to the interaction 
with CBFβ is not clear. We mutated CBFβ residues W73–
R78, which are not resolved in the pentameric structure 
[10] and are part of the previously reported CBFβ dele-
tion mutant (amino acids 69–90) that abrogated its bind-
ing to HIV-1 Vif [5]. Our double-alanine substitution 
study showed that these CBFβ residues did not signifi-
cantly contribute to Vif binding. Our results likely differ 
because the previous study analyzed a larger deletion 
compared to the region analyzed in our study (amino 
acids 69–90 vs. 75–81). The deletion most likely affected 
the overall structure of CBFβ, which resulted in loss of 
Vif binding; the double-alanine substitution mutants ana-
lyzed in our study did not have an effect on the structure 





















































































CBFβ siRNA Ctrl siRNA 
Fig. 7 The tripartite interaction between I55 and F68 of CBFβ and W5 of Vif is sufficient to stabilize Vif–CBFβ interaction. a After treatment of 293T 
cells with CBFβ‑specific siRNA, the cells were co‑transfected with WT Flag‑CBFβ or substitution mutants of Flag‑CBFβ and WT Vif. The cells were 
treated with MG132 (5 μM) for 16‑h before cell lysates were harvested. Immunoblots of cell lysates (upper three panels) and co‑IP samples (lower two 
panels) probed for Flag‑CBFβ, endogenous CBFβ, Vif, and tubulin (loading control) are shown. b Average immunoprecipitation efficiency of WT Vif 
with CBFβ mutants relative to WT CBFβ (set to 100%). Statistical significance was determined using t test; *P < 0.05. c The model depicts Vif (red) and 
CBFβ (cyan) adapted from PDB: 4N9F. The tripartite hydrophobic interaction of I55 (magenta) and F68 (magenta) of CBFβ and W5 (blue) of Vif are 
highlighted in black frame and a close‑up of the highlighted residues is shown with the approximated distance between them in Å
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E45–S52 do not compose a bona fide CBFβ interaction 
site; it is possible that substitution mutations of Vif resi-
dues E45–S52 may have indirectly affected the structure 
of Vif, resulting in a weaker interaction between W5 and 
I55 or F68. Although it was not discussed previously, we 
noted a potential electrostatic interaction between CBFβ 
E54 and Vif K50. Interestingly, CBFβ E54 is adjacent to 
I55, which is involved in the tripartite interaction; disrup-
tion of a potential electrostatic interaction between Vif 
K50 and CBFβ E54 may have indirectly influenced the 
I55 residue position, leading to a weaker binding to Vif.
The results of these studies indicate that Vif–CBFβ and 
Vif-APOBEC3 interaction surfaces do not overlap and 
are mutually exclusive. Mutations in the 14DRMR17 and 
40YRHHY44 motifs, which were previously shown to be 
essential for degradation of A3F and A3G, respectively, 
did not have any effect on the Vif–CBFβ interaction. 
We also found that several Vif amino acids, including 
H27, H28, W38, and others are likely to be involved in a 
hydrophobic interaction that is essential for maintaining 
the structure of the α-domain of Vif and are not directly 
involved in interaction with CBFβ. These results are con-
sistent with prior mutagenesis studies [17].
Results of prior mutagenesis studies [19, 23, 24] and 
the current study on the effect of residues H27, H28, 
W38, T47, N48, P49, K50, I57, P58, and F112 mutants of 
Vif on binding to CBFβ and APOBEC3 proteins can be 
interpreted and grouped into those that participate in an 
extensive hydrophobic interaction and those that main-
tain the structure of the α-domain of Vif. Previous stud-
ies found that the W21A mutant was unable to bind to 
CBFβ [5, 6, 17, 18], while our studies indicate that the 
W21A–K22A double mutant does not have any appar-
ent defect in CBFβ binding. Examination of the penta-
meric crystal structure shows that the W21 residue of Vif 
is buried within the α-domain motif of Vif and does not 
interact with CBFβ; SASA for W21 is 6.49 Å2. Thus, the 
W21A mutation most likely results in a major structural 
change in the α-domain of Vif, resulting in loss of binding 
to CBFβ. Interestingly, our results suggest that the lysine 
residue at the 22 position is required for the structural 
changes induced by the W21A mutation.
The pentameric structure of Vif in complex with CBFβ 
suggests other potential interactions between Vif and 
CBFβ. Vif residues W89 is close to CBFβ residue F143, 
and Vif Y94 is in close proximity to CBFβ I102, E135, 
D136, and Q140. In addition, Vif C-terminal residues 
near F115 are in close proximity to CBFβ residue F153 
and other residues between 151 and 156. Although these 
interactions likely stabilize Vif–CBFβ binding, they are 
not sufficient to retain Vif activity, since mutations at 
W5 of Vif, or I55 and/or F68 of CBFβ were sufficient to 
almost completely inhibit Vif ’s ability to bind to CBFβ 
and induce A3G degradation. Although these interac-
tions are not sufficient to support Vif function, additional 
studies are needed to determine whether other mutations 
at these sites can result in steric hindrance and interfere 
with Vif–CBFβ binding. Similarly, the functional signifi-
cance of Vif–Cul5 and Vif–EloC interactions described in 
the pentameric structure should be determined to estab-
lish whether these interactions may be valuable targets 
for development of small molecule inhibitors.
Conclusions
Our results provide detailed insight into the critical 
determinants of the interaction interface between the 
N-terminus of Vif and CBFβ and identified a tripartite 
interaction that plays a major role in Vif–CBFβ binding. 
Together with the available structural data on Vif–CBFβ–
E3 ubiquitin ligase complex, these results further our 
understanding of the biology of HIV-1 Vif–CBFβ inter-
action and may aid in the development of novel thera-
peutics that target the Vif–CBFβ interaction and inhibit 
Vif-mediated degradation of A3 proteins.
Methods
Plasmids and cell lines
Expression plasmids of Flag-A3G, HIV-1 Vif and its 
N-terminal double-alanine substitution mutants, HIV-1 
vector HDV-eGFP, and VSV-G expression plasmid 
phCMV-G were previously described [19, 25–31]. All 
Vif mutants were generated by site-directed mutagenesis 
using a QuickChange Lightening site-directed mutagene-
sis kit (Agilent Technologies) and verified by sequencing. 
The Flag-CBFβ expression plasmid was obtained from 
Addgene.
HeLa-derived reporter TZM-bl and 293T cell lines 
were maintained in DMEM (Corning Cellgro) supple-
mented with 10% fetal bovine serum (HyClone) and 1% 
penicillin–streptomycin (GIBCO).
Co‑immunoprecipitation assays and western blotting
Flag Co-IP assays were carried out as previously 
described [19, 25]. Briefly, 293T cells were seeded at 
4 × 106 cells per 10-cm dish and transfected the next day 
by the polyethylenimine PEI method [19, 32]. The follow-
ing DNA amounts were used to transfect 293T cells: 4 μg 
Flag-CBFβ, 4 μg Vif, and 1.8 μg pGreen Lantern-1 (pGL) 
(GIBCO; control for transfections) expression plasmids. 
To maintain equivalent DNA amounts, pcDNA3.1 was 
used when needed. After 48 h, total cell lysates were har-
vested in 1 mL of lysis buffer and Co-IP was performed 
as previously described [19, 25]. To detect eluted com-
plexes as well as the input cell lysates, western blotting 
was performed. CBFβ was detected using a rabbit anti-
Flag polyclonal antibody (Sigma) at a 1:2000 dilution, 
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Vif was detected using a mouse anti-Vif monoclonal 
antibody [Clone 319] (ab66643; Abcam) at a 1:2000 dilu-
tion, and tubulin as loading control was detected using 
mouse anti-tubulin antibody (Sigma) at a 1:20,000 dilu-
tion. Rabbit and mouse primary antibodies were detected 
using 1:5000 dilutions of an IRDye® 800CW-labeled goat 
anti-rabbit secondary antibody (Licor) or an IRDye® 
680-labeled goat anti-mouse secondary antibody (Licor). 
Protein bands were visualized and quantified using an 
Odyssey® Infrared Imaging System (Licor).
A3G degradation assays
Human 293T cells were seeded at 8 × 105 cells per well 
in six-well plates and transfections were carried out 
using the PEI method. To assay for Vif-mediated degra-
dation of A3G, the following plasmids and amounts were 
used: 0.34 and 0.67  μg of pFlag-A3G, 2.5  μg of Vif, and 
0.2 μg pGL (used as a positive control for transfection). 
To maintain equivalent DNA amount, pcDNA3.1 was 
added as needed. After 48 h, cell lysates were harvested 
and immunoblotting analyses were performed to detect 
steady-state expression levels of A3G in the absence or 
presence of Vif. Flag-A3G was detected using a rabbit 
anti-Flag polyclonal antibody (Sigma). HIV-1 Vif, endog-
enous CBFβ and tubulin were probed as described above.
Virus production
To produce virus, 293T cells were seeded at 8 × 105 cells 
per well in six-well plates, and transfected using the PEI 
method with the following plasmids and amounts: 1  μg 
of pHDV-eGFP, 0.25 μg of phCMV-G, 0.34 μg or 0.67 μg 
of pFlag-A3G, and 2.5  μg of Vif. To produce virus with 
or without CBFβ depletion, 293T cells were seeded at 
2.5  ×  105 cells per well in six-well plates a day before 
transfection and the Lipofectamine2000 transfec-
tion method (Invitrogen) was used with the following 
plasmids and amounts: 1  μg of pHDV-eGFP, 0.25  μg of 
phCMV-G, 0.34 μg or 0.67 μg of pFlag-A3G, and 2.5 μg of 
Vif in combination with the specific siRNA as described 
below. After 48 h, the virus-containing supernatants were 
filtered through 0.45-μm filter and kept at −80  °C until 
use.
Virus infectivity
TZM-bl cells were seeded in 96-well plates (4 × 103 cells 
per well) and were infected the next day in triplicate with 
viruses normalized for p24 as determined by p24 ELISA 
(XpressBio). Forty-eight hours later, luciferase activ-
ity was determined by britelite™ plus kit (PerkinElmer) 
following the instructions of the manufacturer using a 
LUMIstar Galaxy luminometer or 1450 MicroBeta JET 
(PerkinElmer).
CBFβ knockdown
For CBFβ knockdown experiments, 293T cells were 
seeded at 2.5 × 105 cells per well in six-well plates a day 
before transfection. Small interfering RNA (siRNA)-
mediated transient knockdown of CBFβ was performed 
using Silencer select CBFβ siRNA targeting coding 
region (Ambion; S2470) or siRNA-B07 targeting 3′-UTR 
region (Invitrogen; NM_022845.2_stealth_865), which 
was designed based on an shRNA described previously 
[4] and control siRNA at 25  nM using Lipofectamine 
RNAiMax reagent (Invitrogen) following the manufac-
turer instructions. Twenty-four hours later the cells were 
co-transfected with the respective siRNA (25  nM) and 
expression plasmids of Flag-A3G, Vif, VSV-G, and HDV-
eGFP vector using Lipofectamine2000 reagent in order 
to produce virus for infectivity (see above for details of 
the amounts of plasmids used) and maintain efficient 
CBFβ knockdown. In some CBFβ overexpression rescue 
experiments, in addition to the above co-transfection 
cocktails of plasmids, we added either wild-type or dif-
ferent mutants (I55A, I55D, F68A, F68D, I55A-F68D, or 
I55D-F68D) of CBFβ expression plasmids and carried 
out infectivity and A3G degradation assays as described 
above. After 48 h, producer cell lysates and supernatants 
were collected for western blotting and infectivity assays, 
respectively.
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